Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis.


Journal

SLAS technology
ISSN: 2472-6311
Titre abrégé: SLAS Technol
Pays: United States
ID NLM: 101697564

Informations de publication

Date de publication:
10 2022
Historique:
received: 16 05 2022
revised: 20 07 2022
accepted: 24 07 2022
pubmed: 1 8 2022
medline: 12 10 2022
entrez: 31 7 2022
Statut: ppublish

Résumé

There is currently no diagnostic or prognostic biomarker available in clinical practice for Amyotrophic Lateral Sclerosis (ALS). The objective of this study was to monitor a combination of various inflammatory markers, lipids, and apolipoproteins alterations in ALS patients at the time of diagnosis, to assess their role as early diagnostic or prognostic biomarker candidates. C-reactive protein, orosomucoid, prealbumin, calprotectin, lipids and apoliproteins were determined in the blood of all subjects (25 ALS patients, 23 controls) as routinely performed in our laboratory. Inflammatory mediators were evaluated by a bead-based multiplex assay. A two-step approach was used for each analytical strategy: univariate analysis followed by multivariate analysis. Eight features were significantly different between ALS patients and controls, sometimes with important fold changes. The supervised Partial least Squares Discriminant Analysis separated ALS and controls with great accuracy (94 %) and the permutation test was significant (p < 0.01), ensuring the robustness of the model. The prediction model leads to a mean sensitivity and specificity of 90 (+/- 10) and 78 (+/- 10) %, respectively, with a mean predictive positive value and negative predictive value of 80 (+/- 8.9) and 89 (+/- 11.8) %, respectively. However, the models did not discriminate subgroups of ALS patients based on ALS characteristics. This study highlights the usefulness of evaluating a combination of multiple pathways rather than focusing on a single target. These promising results suggest the need for the longitudinal monitoring of these candidates to determine their role in disease evolution.

Identifiants

pubmed: 35908647
pii: S2472-6303(22)05165-2
doi: 10.1016/j.slast.2022.07.003
pii:
doi:

Substances chimiques

Apolipoproteins 0
Biomarkers 0
Inflammation Mediators 0
Leukocyte L1 Antigen Complex 0
Lipids 0
Lipoproteins 0
Orosomucoid 0
Prealbumin 0
C-Reactive Protein 9007-41-4

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

327-334

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hugo Alarcan (H)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France. Electronic address: hugo.alarcan@univ-tours.fr.

Mélanie Berthet (M)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France.

Laura Suire (L)

Laboratoire de biochimie, CHRU Trousseau, avenue de la République, 37170 Chambray-lès-Tours, France.

Corentin Colas (C)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France.

Loïc Gonzalez (L)

UMR1100 « Infection respiratoire & Immunité », Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France.

Christophe Paget (C)

UMR1100 « Infection respiratoire & Immunité », Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France.

Isabelle Benz-de Bretagne (I)

Laboratoire de biochimie, CHRU Trousseau, avenue de la République, 37170 Chambray-lès-Tours, France.

Eric Piver (E)

Laboratoire de biochimie, CHRU Trousseau, avenue de la République, 37170 Chambray-lès-Tours, France.

Patrick Vourc'h (P)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France; UMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France.

Christian Andres (C)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France; UMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France.

Philippe Corcia (P)

UMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France; Service de neurologie, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France.

Hélène Blasco (H)

Laboratoire de biochimie et biologie moléculaire, CHRU Bretonneau, 2 Boulevard Tonnellé, 37000 Tours, France; UMR 1253 iBrain, Université de Tours, Inserm, 10 Boulevard Tonnellé, 37000 Tours, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH